Atonomics reaches agreement to advance development of diagnostic test for lifestyle diseases

NewsGuard 100/100 Score

Investment will Aid Atonomics in Development of an Advanced Platform for Testing of Lifestyle Diseases

Atonomics announces today that it has entered into an agreement with Omron Healthcare, which will enable Atonomics to advance the development of the Atolyzer®Consumer device for advanced diagnostic testing of lifestyle diseases in a consumer pharmacy setting. As part of the transaction Omron Healthcare is taking a minority equity stake in Atonomics.

The Atolyzer®Consumer device is the initial product line under the Atolyzer®Platform, a fully integrated immuno-, metabolic-, and molecular diagnostic platform, designed to deliver central laboratory performance in a near-patient environment. The platform consists of three devices currently under development: Atolyzer®Consumer, Atolyzer®PoC and Atolyzer®Gene.

Atonomics is targeting to create a paradigm shift in how lifestyle diseases are managed today. "We want to change the way people are going to controls at the GP office for a yearly check-up of their type-2 diabetes or heart problem to be able in the future additionally to monitor and manage their disease status actively towards less disease complications and simply a better quality of life," says Thomas Warthoe, Atonomics' CEO.

"The Atolyzer®Consumer device combines small size, ease of use, portability and low cost in a system that is based on well-established chemistries, reagents, and technologies. We look forward to assisting Atonomics in moving this technology towards commercialization," says Kiichiro Miyata, President and CEO of Omron Healthcare.

This collaboration re-emphasizes the development pathway that Atonomics has embarked upon, and duly stresses the need to offer cost effective convenience based point-of care diagnostics in the molecular space. We welcome the addition to our existing impressive syndicate, which includes Beckman Coulter, of Omron, a world-class consumer-oriented company, which has clearly recognized our strategic vision. We look forward to working together in bringing this offering to the consumer", says Ashok Dhanrajgir, Board Director at Atonomics and Senior Partner at Inventages.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Does living near green space help soothe early childhood anxiety and depression?